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Abstract The dihydropyridine-sensitive calcium channel agonist 
(-)-BayK 8644 was found to produce an enhancement of the 
intrinsic hydrolysis of GTP by Go in rat frontal cortex mem- 
branes. An anti-calcium channel i~-subunit antiserum abolished 
the (-)-BayK 8644-stimulated hydrolysis of GTP by Go and 
reduced the dihydropyridine binding capacity of the cortical mem- 
branes. A peptide which mimics the O-subunit binding domain of 
the calcium channel complex, also attenuated (-)-BayK 8644 
activation of GTPase. This study suggests that the calcium chan- 
nel l~-subunit is the principal component of the channel complex 
involved in linking dihydropyridine agonist binding to enhanced 
hydrolysis of GTP by G o. This may be a mechanism by which 
calcium channels can normally act to limit the duration of a 
G-protein modulatory signal. 
Key words': Calcium channel fl-subunit; G-protein Go; 
GTP hydrolysis 
1. Introduction 
Neuronal voltage-dependent calcium channels (VDCCs) 
have been shown to be modulated by a variety of neurotrans- 
mitters via an interaction with pertussis toxin (PTX) sensitive 
GTP-binding proteins (G-proteins) [1]. It has been suggested 
that the Go subtype of G-protein may be pivotal in mediating 
the neurotransmitter inhibition of Ca 2+ channel currents [2,3,4]. 
In many neuronal systems, neurotransmitters inhibit N and 
P/Q type VDCCs [1] with a smaller effect on L-type VDCCs 
[5,6]. L-type VDCCs are the primary target for modulation in 
neurosecretory [3] and non-neuronal secretory cells [7]. 
G-Proteins have also been found to modulate the interaction 
of dihydropyridine (DHP) agonists with L-type Ca 2+ channels. 
The agonist effects of DHPs on dorsal root ganglion neuron 
Ca 2+ currents is promoted upon activation of a PTX-sensitive 
G-protein [8] and GTP analogues have been shown to enhance 
DHP agonist binding to cortical synaptic membranes [9]. The 
L-type VDCC has a subunit composition of four non-co- 
valently linked heterologous polypeptides (~,  ~2-g, fl and y) 
[10]. The ~1 subunit forms a functional ion pore which binds 
DHPs [11] and can be modulated by binding of the VDCC fl 
subunit [12,13,14]. By the use of antisense oligonucleotides 
complementary to the mRNA of all four cloned VDCC 
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fl-subunits we have also revealed the importance of endogenous 
fl-subunits in the amplitude, activation kinetics, DHP modula- 
tion [15] and G-protein modulation [6] of Ca :+ channel currents 
in cultured dorsal root ganglion neurones. 
G-Protein c~-subunits have an intrinsic GTPase activity 
which hydrolyses GTP, bound to the activated form of the 
G-protein c~-subunit, o GDR thereby inactivating and recy- 
cling the G-protein [16]. Activation of a G-protein linked neu- 
rotransmitter receptor esults in an increase in GTPase activity 
due to an increased exchange of GDP for GTP [17,18]. How- 
ever, GTPase can also be potentiated by an effector protein 
acting as a GTPase-activating-protein (GAP) to stimulate the 
intrinsic GTPase activity [19,20,21]. It has been shown previ- 
ously that the GTPase activity of the G-protein Go can be 
stimulated by a number of DHP agonists [22]. Using an anti- 
peptide anti-VDCC fl-subunit antiserum and a peptide, which 
mimics the fl subunit binding site on the VDCC c~-subunit [23], 
we now provide evidence that the VDCC fl-subunit is the prin- 
cipal component of the L-type calcium channel involved in 
linking DHP agonist binding with enhanced GTPase activity 
of the L-type VDCC associated G-protein. 
2. Materials and methods 
2.1. GTPase assay 
The frontal cortex membrane preparation and GTPase assay were 
performed as described previously [22]. 
2.2. [3H]PN200 110 binding 
200 ¢tl of membrane suspension and 200 ,ul of either H20 or 10/tM 
nicardipine (to assess non-specific binding) were added in duplicate to 
5 ml tubes containing 500 ¢tl of binding buffer of the following compo- 
sition (raM): NaCI 132, KCI 5, CaC12 1.2, MgCI 2 1.3, glucose 10, 
Tris-hydoxymethylaminomethane 25; adjusted to pH 7.4 with HCI. 
This binding buffer also contained [3H]PN200 110 (Amersham) at a 
range of concentrations ( M): 0.5, 1.0, 2.0, 5.0, 10.0 in order to deter- 
mine Bm,,x and Kj using Scatchard transformation a alysis. Following 
incubation at 25°C for 60 min the reaction was terminated by filtration 
through GF/B filters (Whatman). The filters were washed with 3 x 3 ml 
volumes of ice-cold Tris-HC1 buffer (50 mM, pH 7.4) and then counted 
for 3H content in a liquid scintillation counter in a 2 ml volume of 
scintillation fluid (Hionic-Fluor). All experiments using DHPs were 
performed using sodium lighting. 
2.3. Incubation of membranes with antisera 
Membranes were incubated at 30°C for 60 min with either VDCC 
fl-subunit antiserum (dilution 1 : 50), VDCC ~2-subunit antiserum (dilu- 
tion 1 : 50) or corresponding pre-immune antisera (dilution 1 : 50). The 
fl-subunit antiserum has been characterised previously [15] and the 
c~2-subunit antiserum characterisation s described in [24]. An antipep- 
tide anti-G protein antibody which recognised the peptide sequence 
ANNLRGCGLY on the ~ subunit of Go was raised, affinity-purified 
and characterised using the procedures described in [4]. The affinity- 
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purified anti-G, antibody was also raised and characterised asdescribed 
in [4]. Membranes were incubated at 30°C for 60 min with the anti-G- 
protein antibodies (50 Hg/ml) or control rabbit IgG (50/lg/ml). 
2.4. Production of VDCC fl-subunit site peptide 
The peptide sequences u ed in this study were synthesized and puri- 
fied using previously described procedures [25,26]. The VDCC fl-site 
peptide used in this study had the sequence: QQLEEDLKGYLDWI, 
which is homologous to the VDCC fl-~ interaction site described in 
[23]. This peptide sequence corresponds toamino acids 428~,41 in the 
rat brain Sic and ~m calcium channel clones, which are located on the 
cytoplasmic loop linking transmembrane domains I and II. The control 
scrambled peptide had the sequence: GYLLEDEKWILDQQ; this pep- 
tide has no significant homology with any other peptide sequence inthe 
Genbank/EMBL databases. 
The membranes were incubated with the peptides (20 ,ug/ml; 10/IM) 
for 1 h at 30°C prior to the experiment. 
2.5. Transient calcium channel subunit expression i  COS-7 cells 
COS-7 cells were grown to confluency inc~MEM (Gibco/Life) contain- 
ing 10% newborn calf serum. Cells were transfected with approximately 
20/lg of the appropriate pMT2 construct by electroporation (Electro- 
poratorlI-Invitrogen) i  500/zl of phosphate-buffered saline (PBS), 
pH 7.4. Three days after transfection the cells were harvested in homogen- 
ising buffer (10 mM HEPES, pH 7.4, 10% w/v sucrose, 1 mM EDTA, 
1 mM PMSF, 25 trypsin inhibitor units/ml aprotinin, 50/~M leupeptin, 
0.1 mg/ml soy bean trypsin inhibitor) at 4°C. Membrane preparation, 
electrophoresis and immunoblotting were performed essentially as pre- 
viously described [15]. 
3. Results and discussion 
Binding of the agonist isomer of (-)-BayK 8644 [27] to the 
L-type calcium channel caused an increase in high affinity 
GTPase activity in the rat frontal cortex (Fig. 1). The maximally 
effective concentration was 10-100 nM which produced ap- 
proximately 20% stimulation of GTPase. In the present study, 
the weak antagonist isomer, (+)-BayK 8644 [27], was unable to 
induce any stimulation of GTP hydrolysis (a maximal 
3.72 + 0.63% stimulation of GTPase being observed at 100 nM; 
Fig. 1). From this we conclude that the GTPase stimulation 
induced by DHPs occurs when the L-type calcium channel is 
in the DHP agonist bound conformation. The present study 
supports the finding of [22,28], which showed an enhancement 
of GTPase by racemic BayK 8644. It was also found [22] that 
the stimulation of GTPase by DHP agonists was due to a 
stimulation of the intrinsic GTPase activity of the G-protein 
and not due to an increase in the rate of guanine nucleotide 
exchange, which was the case for GABAa-ergic stimulation of 
GTP hydrolysis. 
We examined the effect of affinity-purified anti-G-protein 
antibodies, pecific to the ~ subunit of either Gi or Go, on the 
DHP agonist and GABAB receptor mediated enhancement of
GTPase. The specificity of the G-protein antibodies used in this 
study has been confirmed previously [4]. Treatment of the cor- 
tical membrane with the anti-Go antibody caused an 84 + 5% 
reduction in the stimulation of GTPase by the DHP agonist 
(Fig. 2A), the reduction in GTPase activity was prevented by 
preadsorption f the anti-G o antibody with its immunising pep- 
tide (500/2g/ml, 1 h, 30°C); the stimulation of GTPase by 
(-)-BayK 8644 was then 15 + 1.8% (n = 6). The anti-G~ anti- 
body had no effect on DHP agonist-stimulation f GTPase 
(Fig. 2A). In contrast, GABAB receptor stimulation of high 
affinity GTPase was reduced by 89 + 4% and 41 + 5% follow- 
ing treatment with the anti-G~ antibody and anti-G o antibody, 
respectively (Fig. 2B), indicating that the GABAB receptor can 
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Fig. 1. A concentration-response curve for the stimulation of GTPase 
by the L-type calcium channel activator (-)-BayK 8644 and L-type 
calcium channel antagonist (+)-BayK 8644. Basal GTPase activity was 
33 + 6 pmol/mg/min (  = 9) and stimulation by (-)-BayK 8644 (o) or 
(+)-BayK 8644 (©) is expressed as % stimulation of GTPase above basal 
activity. Results are presented as mean + S.E.M. and the number of 
experiments is given in parentheses. 
interact with both G~ and Go in this preparation. Preadsorption 
of the anti-G-protein antibodies with their respective immuni- 
sing peptides (500/2g/ml, 1h, 30°C) specifically prevented the 
inhibition of the GABABergic-stimulation of GTPase 
(21 + 2.1%, n = 6 and 22 + 3%, n = 7 stimulation of GTPase by 
(-)-baclofen was observed following pretreatment of the anti- 
G~ and anti-Go antibodies, respectively, with their immunising 
peptides). GABAa receptors have also been reported to couple 
to both Go and Gil in bovine brain [29]. However, it would 
appear that only the coupling of GABAB receptors via Go is 
involved in the inhibition of calcium channel currents [4,30]. 
The present study, and that of [22], have shown that the 
L-type calcium channel, in its DHP agonist bound conforma- 
tion, promotes the GTPase activity exclusively of Go. It is 
possible that in intact polarised systems a significant propor- 
tion of L-type VDCCs are normally in this conformation. Since 
Go is the principal G-protein involved in mediating the neuro- 
transmitter modulation of the calcium channel current, this 
enhanced GTPase activity may be the mechanism by which the 
channel can deactivate such a modulatory signal. A similar 
mechanism exists for deactivation of the modulatory effects of 
Gq/11, induced upon activation of muscarinic receptors [21]. 
Those authors demonstrated an enhanced GTP hydrolysis of 
Gq/H by its effector protein, phospholipase C. It has also been 
reported that the GTPase activity of transducin, the photore- 
ceptor G-protein, is promoted by its effector cGMP phospho- 
diesterase [19,20]. 
By using an antipeptide antibody raised against he VDCC 
fl-subunit we have found that the VDCC fl-subunit has a role 
in coupling DHP agonist binding to the enhanced GTPase 
activity of Go. The anti VDCC fl-subunit antiserum used in this 
study was raised against a VDCC fl-subunit peptide as previ- 
ously described [15]. The anti-fl-subunit antiserum recognised 
]~lb, ]~3 and Ha overexpressed in COS cells (Fig. 3A). In the 
presence of preimmune serum, Eadie-Hofstee analysis howed 
a 31 + 6% increase in GTPase Vmax with no change in Km for 
GTP by 10 nM (-)-BayK 8644 (Fig. 3B). However, this stimu- 
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Fig. 2. Effect of anti G-protein antibodies on (-)-BayK 8644 and (-)-baclofen stimulation of GTPase. (A) An affinity purified anti-Gt antibody (50 
/zg/ml) (~'~) had no effect on the ability of (-)-BayK 8644 to stimulate GTPase. Stimulation of GTPase by (-)-BayK 8644 was reduced by 84 + 5% 
when the membranes were pretreated with an affinity-purified anti-G o antibody (50/zg/ml) (~'~) (n = 6, **P < 0.0l, paired t-test compared to 
membranes treated with control rabbit IgG (am). (B) Baclofen-stimulated GTPase was attenuated by 89 + 4% and 41 + 5% when the membranes 
were treated with affinity-purified anti-Gi (~)  and anti-G o (~)  antibodies respectively (n = 8, **2P < 0.01, paired t-test compared to membranes 
treated with control rabbit IgG). 
lation of GTP hydrolysis by the DHP agonist was abolished 
following incubation with the VDCC fl-subunit antiserum (Fig. 
3B,C). Following preadsorption of the anti-fl-subunit antise- 
rum with its immunising peptide, no attenuation i (-)-BayK 
8644-stimulation f GTPase was observed (Fig. 3C). 
We have reported that the VDCC fl-subunit has a role in the 
G-protein mediated inhibition of the calcium channel current 
in DRGs [6]. The inhibition of the calcium channel current by 
the GABA~ agonist (-)-baclofen was potentiated following an- 
tisense oligonucleotide-depletion of VDCC fl-subunits from 
these cells. This suggests that in native cells the VDCC fl- 
subunit may act to limit, possibly by competition for a binding 
site, the extent of the interaction between the VDCC ~-subunit 
and Go [6]. This may be facilitated by the VDCC cq-fl-subunit 
complex stimulating hydrolysis of GTP-Go to GDP-Go, and 
thus limiting the temporal effectiveness of the G-protein modu- 
lating signal. 
The primary binding site of the VDCC fl-subunit on the 
cq-subunit is a conserved motif in the I-II cytoplasmic linker 
of the ~l-subunit [23], termed the ~Zl-SUbunit interaction domain 
(AID) [Witcher, D.R., De Waard, M., Liu, H.Y. and Campbell, 
K.P. (1995) Biophys. J. 68, M-AM-H2]. The fl-site peptide 
sequence used in this study is homologous to the AID. The 
synthetic fl-site peptide should thus compete with the AID for 
interaction with the fl-subunit, thereby disrupting the associa- 
tion between the VDCC~l-subunit and its cytoplasmic fl-sub- 
unit. The use of this peptide in the GTPase assay system abol- 
ished the stimulation of GTP hydrolysis by (-)-BayK 8644 (Fig. 
4A) but had no effect on the GABAB-mediated stimulation of 
GTPase (% stimulation of GTPase by 10/.tM (-)-baclofen was 
30.8 + 3.0% and 24.0 + 2.5% in the presence of the control 
scrambled peptide and fl-site peptide, respectively; Fig. 4B). 
This result suggests that the VDCC fl-subunit must be associ- 
ated with the L-type VDCC ~l-SUbunit in order to permit the 
stimulation of GTPase by DHP agonists. This reinforces the 
hypothesis that the fl-subunit is a prerequisite for coupling 
DHP agonist binding to increased GTP hydrolysis. 
The VDCC fl-subunit is involved in modulating DHP bind- 
ing to the VDCC cq-subunit. In several studies co-expression 
of the skeletal muscle VDCC fl-subunit with the ~-subunit 
enhanced high affinity binding of the DHP antagonist ligand 
[3H]PN200 110 to the a~-subunit [31,32,33] although the fl- 
subunit did not appear to increase the expression levels of 
VDCCcq-subunit protein [34,35]. In the present study we have 
observed a 30% reduction in high affinity [3H]PN200 110 bind- 
ing sites with no change in the affinity for DHPs 
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Fig. 3. Effect of VDCC fl-subunit antiserum or pre-immune serum on (-)-BayK 8644 and (-)-baclofen-stimulation of GTPase A. Membranes from 
COS-7 cells transiently expressing either calcium channel ale as a control [36], fl,b [37], f13 or ,84 [38,39] subunits, as labelled, were immunoblotted 
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M, Km in (-)-BayK 8644-stimulated membranes was 0.23 + 0.02 M). In the presence ofanti-VDCCfl-subunit antiserum basal GTPase Vm~x was 88 + 9 
pmol/mg/min (basal Km = 0.24 + 0.01 M), the subsequent addition of 10 nM (-)-BayK 8644 had no effect on Vmax (78 + 10 pmol/mg/min) or on Km 
for GTP (0.23 + 0.007 M) (n = 9). (C) Stimulation of GTPase (at 0.5 M GTP) by 10 nM (-)-BayK 8644 was abolished by pretreatment of the 
membrane with anti-VDCC fl-subunit antiserum (dilution 1 : 50) (m) (n = 20, **2P < 0.01, paired t-test compared to membranes treated with control 
preimmune serum (n). In contrast, stimulation of GTPase by the GABAn agonist (-)-baclofen (10 BM) (24.0 + 3.6%) was unaffected by pretreat- 
ment of the membrane with anti-VDCC fl-subunit antiserum (24.02 _+ 5.42%) (m) (n--14). Preadsorption of the anti-fl-subunit anti- 
serum with its immunising peptide (Il l), (100 pg/ml, 1 h, 30°C) prevented its effect on (-)-BayK 8644 (10 nM) stimulation of GTPase (14.4 + 2.15%, 
n = 5) and had no effect on the stimulation of GTPase by (-)-baclofen (10 pM), (20.4 + 4.17%, n = 5). 
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reduction in the number of high affinity DHP binding sites 
could contribute to the observed decrease in DHP agonist- 
stimulated GTPase following incubation with the VDCC fl- 
subunit antiserum. However, since the DHP agonist-mediated 
inhibition of GTP hydrolysis was completely abolished by this 
antiserum while the number of available DHP binding sites was 
only partially reduced, we propose that the decrease in DHP 
agonist-stimulation f GTPase by VDCC fl subunit antiserum 
is at least in part downstream of agonist binding. 
The findings presented in this study indicate that the VDCC 
fl-subunit has a role in modulating the DHP binding site on the 
VDCC cd-subunit in the rat frontal cortex membranes. The 
VDCC fl-subunit is also the principal subunit involved in the 
coupling of DHP agonist binding to enhanced GTPase of the 
G-protein Go. The proclivity of the VDCC fl-subunit o stimu- 
late hydrolysis of Go may represent a mechanism by which the 
effector calcium channel deactivates the G-protein modulating 
signal. 
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